News & Publications

Catch up with the latest updates, news and publications from the Virtuoso team.

News

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Reference Publications

Technology

Lee et al. “Cell-type specific potent Wnt signaling blockade by bispecific antibody” Sci Reports (2018)

ICAM-1

CD38

CD47

Posters

VBI-002, a CD47xICAM-1 Bispecific Antibody for the Treatment of Hepatocellular Carcinoma, Melanoma and Non-Small Cell Lung Cancers
AACR • April 14-19, 2023; Orlando, Florida
VBI-003, a CD47xEpCAM Bispecific Antibody as a Potential Treatment for Colorectal and Small Cell Lung Cancers
AACR • April 14-19, 2023; Orlando, Florida
A novel topoisomerase I inhibitor-based anti-ICAM-1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors
AACR • April 14-19, 2023; Orlando, Florida
Multiple Modes of Action of the CD38 x ICAM-1 Bispecific Antibody
AACR • April 8-13, 2022; New Orleans, LA
VBI-002, a CD47 x ICAM-1 Bispecific Antibody Represents a Novel Approach for Treating ICAM-1 Overexpressing Tumors
AACR • April 8-13, 2022; New Orleans, LA
CD47 x EpCAM Bispecific Antibody Represents a Novel Approach for Treating EpCAM Overexpressing Solid Tumor
SITC • November 10-14, 2021; Washington, D.C.
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphom
ASH • December 11-14, 2021; Atlanta, GA